


**AMENDMENTS TO THE CLAIMS**

1. (Original) A compound of general formula (I),



any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof,

wherein

Q is  $-\text{CH}_2-\text{CH}_2-$  or  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$  ;

one of  $\text{R}^1$  and  $\text{R}^2$  is  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{R}^3$ ,  $-\text{CH}_2-\text{CH}=\text{CH}-\text{R}^3$ , or  $-\text{CH}_2-\text{C}\equiv\text{C}-\text{R}^3$ ;

wherein  $\text{R}^3$  is aryl or heteroaryl;

which aryl and heteroaryl is optionally substituted with one or more substituents selected from the group consisting of:

halogen, hydroxy, amino, cyano, nitro, trifluoromethyl, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, and alkynyl; and

the other of  $\text{R}^1$  and  $\text{R}^2$  is  $-\text{CO}-\text{R}^4$ ;

wherein  $\text{R}^4$  is alkyl, cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl.

2. (Original) The compound according to claim 1, wherein

Q is  $-\text{CH}_2-\text{CH}_2-$ .

3. (Original) The compound according to claim 1, wherein  
Q is  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ .
4. (Currently Amended) The compound according to ~~any one of claims 1-3~~ claim 1, wherein  
one of  $\text{R}^1$  and  $\text{R}^2$  is  $-\text{CH}_2-\text{CH}=\text{CH}-\text{R}^3$ ;  
wherein  $\text{R}^3$  is defined as in claim 1.
5. (Currently Amended) The compound according to ~~any one of claims 1-4~~ claim 1, wherein  
 $\text{R}^4$  is alkyl.
6. (Original) The compound according to claim 1, wherein  
Q is  $-\text{CH}_2-\text{CH}_2-$  or  $-\text{CH}_2-\text{CH}_2-\text{CH}_2-$ ;  
one of  $\text{R}^1$  and  $\text{R}^2$  is  $-\text{CH}_2-\text{CH}=\text{CH}-\text{R}^3$ , or  $-\text{CH}_2-\text{C}\equiv\text{C}-\text{R}^3$ ;  
wherein  $\text{R}^3$  is phenyl; and  
the other of  $\text{R}^1$  and  $\text{R}^2$  is  $-\text{CO}-\text{R}^4$ ;  
wherein  $\text{R}^4$  is alkyl.
7. (Original) A compound of claim 1 which is  
( $\pm$ )-1-[9-(3-Phenyl-allyl)-3,9-diaza-bicyclo[4.2.1]non-3-yl]-propan-1-one;  
( $\pm$ )-1-[10-(3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one;  
( $\pm$ )-1-[3-(3-Phenyl-allyl)-3,9-diazabicyclo[4.2.1]non-9-yl]-propan-1-one;

or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.

8. (Currently Amended) A pharmaceutical composition, comprising a therapeutically effective amount of a compound of ~~any one of claims 1-7~~ claim 1, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

9. (Currently Amended) ~~The use of a compound according to any one of claims 1-7, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of the opioid receptor. A method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to modulation of the opioid receptor, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound according to claim 1, or any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.~~

10. (Currently Amended) The ~~use~~method according to claim 9, wherein the disease, disorder or condition responsive to modulation of the opioid receptor is pain, postoperative pain, chronic pain, cancer pain, neuropathic pain, pain during labour and delivery, drug addiction, heroin addiction, cocaine addiction, alcoholism, irritable bowel syndrome, constipation, nausea, vomiting, pruritic dermatoses, allergic dermatitis, atopy, eating disorders, opiate overdoses, depression, smoking, sexual dysfunction, shock, stroke, spinal damage, or head trauma.

11. (Deleted)